Phase I Trial of Radiotherapy Concurrent with Twice-Weekly Gemcitabine for Head and Neck Cancer: Translation From Preclinical Investigations Aiming to Improve the Therapeutic Ratio()()

BACKGROUND: Once-weekly gemcitabine concurrent with radiotherapy was highly effective in the treatment of head and neck cancer (HNC) but limited by high mucosal toxicity. Pre-clinical investigations suggested that delivering gemcitabine at substantially lower doses twice weekly during radiotherapy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Popovtzer, Aron, Normolle, Daniel, Worden, Francis P., Prince, Mark E., Chepeha, Douglas B., Wolf, Gregory T., Bradford, Carol R., Lawrence, Theodore S., Eisbruch, Avraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202797/
https://www.ncbi.nlm.nih.gov/pubmed/25171890
http://dx.doi.org/10.1016/j.tranon.2014.04.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202797/
https://www.ncbi.nlm.nih.gov/pubmed/25171890
http://dx.doi.org/10.1016/j.tranon.2014.04.016

Ejemplares similares